Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study

Öztürk, Kerem; Soylu, Esra; Tolunay, Şahsine; Narter, Selin; Hakyemez, Bahattin

doi:10.1016/j.wneu.2019.04.089

Cited by 5 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…V e might be strongly associated with cellularity because it re ects the amount of extracellular space, as it was exemplarily shown in a glioma model. 33 V p is de ned as the blood per unit volume of tissue recommended as an alternative imaging biomarker for the assessment of blood volume. 34 Our results showed that V e and V p having limited discriminative ability in predicting PTEN expression, indicating no signi cant difference in cellularity among NPC tumors with different degrees of angiogenesis and aggressiveness.…”

Section: Discussionmentioning

confidence: 99%

Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients

Huang

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Objectives: The objective of our study was to investigate whether a phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression was associated with dynamic contrast-enhanced MRI (DCE-MRI) parameters and prognosis in nasopharyngeal carcinoma (NPC). Methods: Two hundred and forty-ve (245) patients with NPC who underwent pretreatment biopsy, PTEN immunohistochemistry of biopsy, and radical intensity-modulated radiation therapy (IMRT) with or without chemotherapy were included. Tumor segmentations were delineated on pretreatment MRI manually. The pharmacokinetic parameters (Ktrans, Kep, Ve, and Vp) derived from dynamic contrastenhanced MRI (DCE-MRI) using the extended Toft's model within the tumor segmentations were estimated. The following demographics and clinical features were assessed and correlated against each other: gender, age, TNM stage, clinical-stage, Epstein-Barr virus (EBV), pathological type, progression-free survival (PFS), and prognosis status. DCE parameter evaluation and clinical feature comparison between the PTEN positive and negative groups was performed and correlation between PTEN expression with the PFS and prognosis status using Cox regression for survival analysis was assessed. Results: A signi cantly lower K trans and K ep were found in NPC tumors in PTEN negative patients than in PTEN positive patients. K trans performed better than K ep in detecting PTEN expression with the ROC AUC of 0.752. PTEN negative was associated with later TNM stage, later clinical-stage, shorter PFS, and worse prognosis. Moreover, N stage, pathological type, K ep , and prognostic status can be considered as independent variables in discrimination of PTEN negative expression in NPCs. Conclusions: PTEN negative indicated a shorter PFS and worse prognosis than PTEN positive in NPC patients. K trans and K ep derived from DCE-MRI, which yielded reliable capability, should be considered as novel image markers that are correlated with PTEN expression and may be used to predict PTEN expression noninvasively. Combined radiological and clinical features can improve the performance of the classi cation of PTEN expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients

Huang

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…IVPS, intravascular compartment (intravascular plasma space); EES, interstitial compartment (extravascular extracellular space); K trans , transfer constant; K ep , washout rate; CBF, tumor blood flow; V e , interstitial volume; V p , blood volume; PS, permeability-surface area product. adults, and DCE TKMs have been used for evaluating the status of these markers in glioma patients (52, [56][57][58][59][60][61][62][63].…”

Section: Correlation With Immunohistochemical Markersmentioning

confidence: 99%

Review of tracer kinetic models in evaluation of gliomas using dynamic contrast-enhanced imaging

Zhou,

Hou,

Tian

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Glioma is the most common type of primary malignant tumor of the central nervous system (CNS), and is characterized by high malignancy, high recurrence rate and poor survival. Conventional imaging techniques only provide information regarding the anatomical location, morphological characteristics, and enhancement patterns. In contrast, advanced imaging techniques such as dynamic contrast-enhanced (DCE) MRI or DCE CT can reflect tissue microcirculation, including tumor vascular hyperplasia and vessel permeability. Although several studies have used DCE imaging to evaluate gliomas, the results of data analysis using conventional tracer kinetic models (TKMs) such as Tofts or extended-Tofts model (ETM) have been ambiguous. More advanced models such as Brix’s conventional two-compartment model (Brix), tissue homogeneity model (TH) and distributed parameter (DP) model have been developed, but their application in clinical trials has been limited. This review attempts to appraise issues on glioma studies using conventional TKMs, such as Tofts or ETM model, highlight advancement of DCE imaging techniques and provides insights on the clinical value of glioma management using more advanced TKMs.

show abstract

“…5,6 For patients with metastases, contrast-enhanced T1WI (CE-T1WI) should be repeatedly performed to assess the progress of brain metastases 7,8 or the efficacy of treatment. 9,10 The conspicuity and detection rate of brain metastases can be improved with a higher dose of gadolinium-based contrast agents (GBCA). 11 However, multiple enhanced examinations or use of higher contrast doses may increase the potential adverse effects, such as nephrogenic systemic fibrosis, 12,13 and may lead to higher gadolinium deposition in the brain 14 or other tissues.…”

mentioning

confidence: 99%

Utility of Contrast-Enhanced T2 FLAIR for Imaging Brain Metastases Using a Half-dose High-Relaxivity Contrast Agent

Jin

Ge²,

Huang³

et al. 2020

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE: Efficient detection of metastases is important for patient' treatment. This prospective study was to explore the clinical value of contrast-enhanced T2 FLAIR in imaging brain metastases using half-dose gadobenate dimeglumine. MATERIALS AND METHODS:In vitro signal intensity of various gadolinium concentrations was explored by spin-echo T1-weighted imaging and T2 FLAIR. Then, 46 patients with lung cancer underwent nonenhanced T2 FLAIR before administration of half-dose gadobenate dimeglumine and 3 consecutive contrast-enhanced T2 FLAIR sequences followed by 1 spin-echo T1WI after administration of half-dose gadobenate dimeglumine. After an additional dose of 0.05 mmol/kg, 3D brain volume imaging was performed. All brain metastases were classified as follows: solid-enhancing, $ 5 mm (group A); ring-enhancing, $ 5 mm (group B); and lesion diameter of ,5 mm (group C). The contrast ratio of the lesions on 3 consecutive phases of contrast-enhanced T2 FLAIR was measured, and the percentage increase of contrast-enhanced T2 FLAIR among the 3 groups was compared. RESULTS:In vitro, the maximal signal intensity was achieved in T2 FLAIR at one-eighth to one-half of the contrast concentration needed for maximal signal intensity in T1WI. In vivo, the mean contrast ratio values of metastases on contrast-enhanced T2 FLAIR for the 3 consecutive phases ranged from 63.64% to 83.05%. The percentage increase (PI) values of contrast-enhanced T2 FLAIR were as follows: PI A , PI B (P ¼ .001) and PI A , PI C (P , .001). The degree of enhancement of brain metastases on contrast-enhanced T2 FLAIR was lower than on 3D brain volume imaging (P , .001) in group A, and higher than on 3D brain volume imaging (P , .001) in group C.CONCLUSIONS: Small or ring-enhancing metastases can be better visualized on delayed contrast-enhanced T2 FLAIR using a halfdose high-relaxivity contrast agent.ABBREVIATIONS: BRAVO ¼ brain volume imaging; CE ¼ contrast-enhanced; CR ¼ contrast ratio; GBCA ¼ gadolinium-based contrast agents; PI ¼ percentage increase B rain metastases occur in approximately 25% of patients with cancer and account for 40% of adult brain tumors. 1 The incidence of brain metastases in patients with lung cancer is highest (19.9%), 2 resulting in high morbidity and mortality. 3 Small metastases, not combined with vasogenic edema or mass effects, are often missed. 1 Improvement of the early detection of small brain

show abstract

Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study

Cited by 5 publications

References 35 publications

Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients

Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients

Review of tracer kinetic models in evaluation of gliomas using dynamic contrast-enhanced imaging

Utility of Contrast-Enhanced T2 FLAIR for Imaging Brain Metastases Using a Half-dose High-Relaxivity Contrast Agent

Contact Info

Product

Resources

About